Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The table below is a review of notable updates that occurred in March 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
| Drug | Pharmacologic Class | Proposed Indication | Status |
| Dermatologic Disorders | |||
| DFD-29 (minocycline hydrochloride; Journey Medical) | Tetracycline antibiotic | Treatment of adults with inflammatory lesions and erythema of rosacea. | NDA accepted |
| Endocrine Disorders | |||
| Paltusotine (Crinetics Pharmaceuticals) | Somatostatin receptor type 2 agonist | Treatment of acromegaly. | Phase 3 trial results |
| Hematological Disorders | |||
| Cevidoplenib (Oscotec) | Spleen tyrosine kinase inhibitor | Treatment of immune thrombocytopenia in patients who have failed to respond or relapsed after prior therapy. | Orphan Drug designation |
| Infectious Diseases | |||
| Pemgarda (pemivibart; Invivyd) | SARS-CoV-2 spike protein-directed attachment inhibitor | For preexposure prophylaxis of COVID-19. | Emergency Use Authorization |
| Metabolic Disorders | |||
| IB1001 (N-acetyl-L-leucine; IntraBio) | Modified amino acid | Treatment of Niemann-Pick disease type C. | NDA accepted for Priority Review |
| Oncology | |||
| Ensartinib (Xcovery) | Anaplastic lymphoma kinase inhibitor | Treatment of adult patients with metastatic ALK-positive non-small cell lung cancer. | NDA accepted for review |
| Psychiatric Disorders | |||
| CYB003 (Cybin) | Psilocybin analog | Treatment of major depressive disorder. | Breakthrough Therapy designation |
| MM120 (lysergide d-tartrate; MindMed) | Synthetic ergotamine | Treatment of generalized anxiety disorder. | Breakthrough Therapy designation |
| Pimavanserin (Acadia Pharmaceuticals) |
Atypical antipsychotic
|
Treatment of negative symptoms of schizophrenia. | Phase 3 trial results |
